PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Virus and Prion Validation, Octapharma Biopharmaceuticals GmbH, Frankfurt, Germany. andreas.volk@octapharma.com.\', \'R&D Plasma, Octapharma Pharmazeutika Produktionsgesellschaft m.b.H., Vienna, Austria.\', \'Virus and Prion Validation, Octapharma Biopharmaceuticals GmbH, Frankfurt, Germany.\', \'ACPS-Network GmbH, Wiesbaden, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1007/s40259-021-00511-9
?:doi
?:hasPublicationType
?:journal
  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
is ?:pmid of
?:pmid
?:pmid
  • 34843105
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34843105>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34843105>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all